Navigation Links
Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
Date:5/18/2009

pport a larger, randomized Phase III study," he says. "This is a Phase II study of this triple combination, so we would need to study this treatment against the standard best two-drug treatment in a randomized Phase III study to know if this triplet is more effective."

"This regimen seems to be a very reasonable choice, and it offers the added advantage that women who use it do not lose their hair," he says. The drug combination used most commonly for patients with HER2+ breast cancer that has spread -- paclitaxel or docetaxel with trastuzumab -- always causes hair loss, Dr. Tan says.

All of the agents are approved for use by the U.S. Food and Drug Administration for cancer, although vinorelbine has not been approved for this particular treatment regimen in the U.S., the researchers say.

Capecitabine chemotherapy is not usually paired with trastuzumab because some studies had suggested it does not offer a synergistic, or additive, benefit. However, Dr. Tan says that newer research has shown the combination is in fact promising.

Among the patients studied, 28 (58 percent) had a partial response, a reduction in the size of the metastatic tumor of more than 30 percent by computed tomography. Four patients had a complete response with no more evidence of metastasized tumors on diagnostic scans, the researchers say.

Average survival was improved when compared historically to traditional treatment, Dr. Tan says. "Normally, survival for metastatic breast cancer is two years," he says. "In this study, average survival was 27 months." He cautioned that these results should be validated in a Phase III study.

"The toxicity was tolerable, no more than is seen with a two-drug regimen," he says. The majority of patients (61 percent) experienced a low white blood count, but only about ten percent of patients had fatigue or other common side effects.

Tan stressed that this
'/>"/>

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
2. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
3. Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
4. Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
5. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
6. Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
7. Large clinical trial finds pirfenidone may help lung function in IPF patients
8. Fewer Than One Percent of Infertile Couples Who Need Treatment Receive It - Website to Bridge Gap Between Infertile Couples and Fertility Clinics
9. Cleveland Clinic CIO Named to Federal Advisory Committee on Health Information Technology
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... is pleased to announce the opening of attendee registration ... Technology Exposition and Conference. This year,s event will be ... Stephens Convention Center in Rosemont, Illinois. OMTEC is the ... industry professionals involved in all facets of the supply ...
... year by a Cornell researcher add to growing evidence that ... of other fruits and vegetables -- can help keep the ... in the Journal of Agricultural and Food Chemistry ... and a member of Cornell,s Institute for Comparative and Environmental ...
... manifested in a variety of tissues and cancer cells ... being studied as a novel treatment. The PPAR-gamma ligand ... differentiation, apoptotic induction, and changes in genes or proteins ... been some reports suggesting that stomach cancer cells manifest ...
... been used as the "gold standard" for the assessment of ... possible complications of this procedure, for both, the physician and ... not trivial one. So, scientists tend to introduce non-invasive methods ... to be published on February 7, 2009 in the ...
... researcher Dr. Daniel Von Hoff and his team at ... developing novel therapies for patients with pancreatic cancer. They ... vulnerability." Dr. Von Hoff provides case studies and ... promising discoveries and is changing the future of oncology ...
... wartime conditions, researchers say , , TUESDAY, Feb. 17 (HealthDay ... be exacerbated by combat conditions in Iraq and Afghanistan ... evacuated for treatment, a new report finds. , In ... for poor morale and combat ineffectiveness, the researchers noted ...
Cached Medicine News:Health News:OMTEC Registration Opens - Education for a Competitive Advantage in Orthopaedics 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells? 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 3Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 4Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Sciences, Inc., a,privately held biopharmaceutical company developing ... BSI-401 inhibited pancreatic cancer,cell growth in vitro ... combination with,oxaliplatin. BSI-401 is BiPar,s second-generation product ... as PARP (poly-ADP-ribose polymerase) inhibitors. Researchers ...
... sleep apnea and sleep behavior,disorders, ROCHESTER, Minn., ... diagnosing and treating patients with a,variety of sleep ... at CHEST 2007, the annual meeting of the ... 20-25. The following are,brief summaries of select presentations., ...
Cached Medicine Technology:BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
VG2 PLIF (Trapezoid) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit co...
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
... Corlok Allografts are unique corticocancellous ... face and a unique Dovetail geometry ... adjacent vertebrae. Corlok Allografts are processed ... spinal allograft implants. Specially designed instruments ...
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Medicine Products: